Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 366

1.

Intestinal gases: influence on gut disorders and the role of dietary manipulations.

Kalantar-Zadeh K, Berean KJ, Burgell RE, Muir JG, Gibson PR.

Nat Rev Gastroenterol Hepatol. 2019 Sep 13. doi: 10.1038/s41575-019-0193-z. [Epub ahead of print] Review.

PMID:
31520080
2.

Dietary fat and the faecal microbiome: where collinearity may lead to incorrect attribution of effects to fat.

Ardalan ZS, Sparrow MP, Muir JG, Gibson PR.

Gut. 2019 Sep 6. pii: gutjnl-2019-319628. doi: 10.1136/gutjnl-2019-319628. [Epub ahead of print] No abstract available.

PMID:
31492690
3.

Clinical coding data algorithm to categorize type of gastrointestinal bleeding as a primary reason for massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry.

Ket SN, Sparrow RL, McQuilten ZK, Tacey M, Gibson PR, Brown GJ, Wood EM.

Vox Sang. 2019 Sep 6. doi: 10.1111/vox.12840. [Epub ahead of print]

PMID:
31489645
4.

Review article: the role of the autonomic nervous system in the pathogenesis and therapy of IBD.

Mogilevski T, Burgell R, Aziz Q, Gibson PR.

Aliment Pharmacol Ther. 2019 Aug 16. doi: 10.1111/apt.15433. [Epub ahead of print] Review.

PMID:
31418887
5.

Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

Garg M, Royce SG, Tikellis C, Shallue C, Batu D, Velkoska E, Burrell LM, Patel SK, Beswick L, Jackson A, Britto K, Lukies M, Sluka P, Wardan H, Hirokawa Y, Tan CW, Faux M, Burgess AW, Hosking P, Monagle S, Thomas M, Gibson PR, Lubel J.

Gut. 2019 Aug 13. pii: gutjnl-2019-318512. doi: 10.1136/gutjnl-2019-318512. [Epub ahead of print]

PMID:
31409604
6.

Will Science Sway Beliefs About Gluten?

Halmos EP, Gibson PR.

Gastroenterology. 2019 Sep;157(3):607-609. doi: 10.1053/j.gastro.2019.06.024. Epub 2019 Jun 21. No abstract available.

PMID:
31233735
7.

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.

Julsgaard M, Hvas CL, Gearry RB, Gibson PR, Fallingborg J, Sparrow MP, Bibby BM, Connell WR, Brown SJ, Kamm MA, Lawrance IC, Vestergaard T, Svenningsen L, Baekdal M, Kammerlander H, Walsh A, Boysen T, Bampton P, Radford-Smith G, Kjeldsen J, Andrews JM, Subramaniam K, Moore GT, Jensen NM, Connor SJ, Wildt S, Wilson B, Ellard K, Christensen LA, Bell SJ.

Inflamm Bowel Dis. 2019 May 29. pii: izz110. doi: 10.1093/ibd/izz110. [Epub ahead of print]

PMID:
31141607
8.

Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis.

Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG.

J Crohns Colitis. 2019 May 15. pii: jjz103. doi: 10.1093/ecco-jcc/jjz103. [Epub ahead of print]

PMID:
31094417
9.

Controversies and reality of the FODMAP diet for patients with irritable bowel syndrome.

Halmos EP, Gibson PR.

J Gastroenterol Hepatol. 2019 Jul;34(7):1134-1142. doi: 10.1111/jgh.14650. Epub 2019 Apr 4. Review.

PMID:
30945376
10.

Letters: low FODMAP diet-directions for future research and the low FODMAP diet is not the only diet for IBS-authors' reply.

Mitchell H, Porter J, Gibson PR, Barrett J, Garg M.

Aliment Pharmacol Ther. 2019 Apr;49(8):1109-1110. doi: 10.1111/apt.15199. No abstract available.

PMID:
30920052
11.

The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status.

Garg M, Royce SG, Tikellis C, Shallue C, Sluka P, Wardan H, Hosking P, Monagle S, Thomas M, Lubel JS, Gibson PR.

Therap Adv Gastroenterol. 2019 Jan 18;12:1756284818822566. doi: 10.1177/1756284818822566. eCollection 2019.

12.

Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease.

Vasudevan A, Gibson PR, Van Langenberg DR.

Inflamm Bowel Dis. 2019 Aug 20;25(9):1462-1473. doi: 10.1093/ibd/izy399.

PMID:
30689858
13.

Reply.

Colombel JF, Shin A, Gibson PR.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):573-574. doi: 10.1016/j.cgh.2018.08.073. No abstract available.

PMID:
30678842
14.

Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems.

Ajamian M, Steer D, Rosella G, Gibson PR.

PLoS One. 2019 Jan 14;14(1):e0210728. doi: 10.1371/journal.pone.0210728. eCollection 2019.

15.

Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome-directions for future research.

Mitchell H, Porter J, Gibson PR, Barrett J, Garg M.

Aliment Pharmacol Ther. 2019 Jan;49(2):124-139. doi: 10.1111/apt.15079. Review.

PMID:
30589971
16.

Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.

Vasudevan A, Raghunath A, Anthony S, Scanlon C, Sparrow MP, Gibson PR, van Langenberg DR.

Dig Dis Sci. 2019 Jun;64(6):1622-1631. doi: 10.1007/s10620-018-5422-8. Epub 2018 Dec 17.

PMID:
30560332
17.

Prebiotics Versus Low FODMAP Diet: An Interpretative Nightmare.

Varney J, Muir JG, Gibson PR.

Gastroenterology. 2019 Mar;156(4):1222. doi: 10.1053/j.gastro.2018.10.060. Epub 2018 Dec 10. No abstract available.

PMID:
30543795
18.

Letter: vedolizumab drug concentrations in neonates following intrauterine exposure.

Flanagan E, Gibson PR, Begun J, Ghaly S, Garg M, Andrews JM, Rosella O, Rosella G, Bell SJ.

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1328-1330. doi: 10.1111/apt.15027. No abstract available.

PMID:
30488628
19.

Review article: emulsifiers in the food supply and implications for gastrointestinal disease.

Halmos EP, Mack A, Gibson PR.

Aliment Pharmacol Ther. 2019 Jan;49(1):41-50. doi: 10.1111/apt.15045. Epub 2018 Nov 28. Review.

PMID:
30484878
20.

Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation).

James SL, van Langenberg DR, Taylor KM, Gibson PR.

JGH Open. 2018 Aug 5;2(5):217-222. doi: 10.1002/jgh3.12076. eCollection 2018 Oct.

21.

Postpolypectomy prophylactic clip closure for the prevention of delayed postpolypectomy bleeding: A systematic review.

Mangira D, Ket SN, Majeed A, Gibson PR, Brown G.

JGH Open. 2018 Mar 25;2(3):105-110. doi: 10.1002/jgh3.12047. eCollection 2018 Jun. Review.

22.
23.

Referrals to a tertiary hospital: A window into clinical management issues in functional gastrointestinal disorders.

Linedale EC, Shahzad MA, Kellie AR, Mikocka-Walus A, Gibson PR, Andrews JM.

JGH Open. 2017 Oct 31;1(3):84-91. doi: 10.1002/jgh3.12015. eCollection 2017 Nov.

24.

A Protocol-Driven Assessment Promotes a More Accurate Diagnosis of Irritable Bowel Syndrome.

Moore JS, Gibson PR, Perry RE, Burgell RE.

Gastroenterol Nurs. 2018 Nov/Dec;41(6):508-515. doi: 10.1097/SGA.0000000000000349.

PMID:
30418343
25.

Gluten-free and low-FODMAP sourdoughs for patients with coeliac disease and irritable bowel syndrome: A clinical perspective.

Muir JG, Varney JE, Ajamian M, Gibson PR.

Int J Food Microbiol. 2019 Feb 2;290:237-246. doi: 10.1016/j.ijfoodmicro.2018.10.016. Epub 2018 Oct 24.

PMID:
30388591
26.

Randomised clinical trial: reducing the intake of dietary FODMAPs of breastfeeding mothers is associated with a greater improvement of the symptoms of infantile colic than for a typical diet.

Iacovou M, Craig SS, Yelland GW, Barrett JS, Gibson PR, Muir JG.

Aliment Pharmacol Ther. 2018 Nov;48(10):1061-1073. doi: 10.1111/apt.15007. Epub 2018 Oct 10.

PMID:
30306603
27.

Efficacy of glutamine in postinfection IBS.

Ford AC, Gibson PR.

Gut. 2019 Oct;68(10):1905-1906. doi: 10.1136/gutjnl-2018-317438. Epub 2018 Sep 22. No abstract available.

PMID:
30244201
28.

AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.

Colombel JF, Shin A, Gibson PR.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):380-390.e1. doi: 10.1016/j.cgh.2018.08.001. Epub 2018 Aug 9. Review.

PMID:
30099108
29.

Culture- and metagenomics-enabled analyses of the Methanosphaera genus reveals their monophyletic origin and differentiation according to genome size.

Hoedt EC, Parks DH, Volmer JG, Rosewarne CP, Denman SE, McSweeney CS, Muir JG, Gibson PR, Cuív PÓ, Hugenholtz P, Tyson GW, Morrison M.

ISME J. 2018 Dec;12(12):2942-2953. doi: 10.1038/s41396-018-0225-7. Epub 2018 Aug 1.

PMID:
30068938
30.

The safety and sensitivity of a telemetric capsule to monitor gastrointestinal hydrogen production in vivo in healthy subjects: a pilot trial comparison to concurrent breath analysis.

Berean KJ, Ha N, Ou JZ, Chrimes AF, Grando D, Yao CK, Muir JG, Ward SA, Burgell RE, Gibson PR, Kalantar-Zadeh K.

Aliment Pharmacol Ther. 2018 Sep;48(6):646-654. doi: 10.1111/apt.14923. Epub 2018 Aug 1.

PMID:
30067289
31.

Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.

Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F.

Inflamm Bowel Dis. 2019 Jan 1;25(1):163-171. doi: 10.1093/ibd/izy229.

PMID:
29982631
32.

Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.

Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C.

J Crohns Colitis. 2018 Jun 18. doi: 10.1093/ecco-jcc/jjy079. [Epub ahead of print]

PMID:
29917070
33.

Reply.

Skodje GI, Henriksen C, Veierød MB, Gibson PR, Lundin KEA.

Gastroenterology. 2018 Jul;155(1):228. doi: 10.1053/j.gastro.2018.06.032. Epub 2018 Jun 9. No abstract available.

PMID:
29894682
34.

Is Non-Celiac Rice-Starch Sensitivity as Common in Children as Non-Celiac Gluten Sensitivity?

Gibson PR, Lundin KEA, Guandalini S.

Am J Gastroenterol. 2018 Aug;113(8):1254. doi: 10.1038/s41395-018-0079-7. Epub 2018 Jun 8. No abstract available.

PMID:
29880973
35.

Illuminating dark depths.

Gibson PR, Burgell RE.

Science. 2018 May 25;360(6391):856-857. doi: 10.1126/science.aat8658. No abstract available.

PMID:
29798870
36.

Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.

Christensen B, Gibson PR, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):486-493. doi: 10.1016/j.cgh.2018.04.060. Epub 2018 May 8.

PMID:
29751166
37.

Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders.

Gill PA, van Zelm MC, Muir JG, Gibson PR.

Aliment Pharmacol Ther. 2018 Jul;48(1):15-34. doi: 10.1111/apt.14689. Epub 2018 May 3. Review.

PMID:
29722430
38.

Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.

Christensen B, Gibson PR, Rubin DT.

Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638. No abstract available.

PMID:
29676007
39.

Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.

Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.

Inflamm Bowel Dis. 2018 Mar 19;24(4):849-860. doi: 10.1093/ibd/izx067.

40.

Modulation of colonic hydrogen sulfide production by diet and mesalazine utilizing a novel gas-profiling technology.

Yao CK, Rotbart A, Ou JZ, Kalantar-Zadeh K, Muir JG, Gibson PR.

Gut Microbes. 2018 Nov 2;9(6):510-522. doi: 10.1080/19490976.2018.1451280. Epub 2018 May 9.

41.

Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).

Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, McKenzie J, Reynolds J, Gibson PR, Hanauer SB, Sparrow MP.

Aliment Pharmacol Ther. 2018 Apr;47(8):1092-1102. doi: 10.1111/apt.14571. Epub 2018 Feb 21.

PMID:
29468701
42.

Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application.

Bryant RV, Friedman AB, Wright EK, Taylor KM, Begun J, Maconi G, Maaser C, Novak KL, Kucharzik T, Atkinson NSS, Asthana A, Gibson PR.

Gut. 2018 May;67(5):973-985. doi: 10.1136/gutjnl-2017-315655. Epub 2018 Feb 3. Review.

PMID:
29437914
43.

The Impact of Mild Heat Stress During Prolonged Running On Gastrointestinal Integrity, Gastrointestinal Symptoms, Systemic Endotoxin and Cytokine Profiles.

Snipe RMJ, Khoo A, Kitic CM, Gibson PR, Costa RJS.

Int J Sports Med. 2018 Feb 7. doi: 10.1055/s-0043-122742. [Epub ahead of print]

PMID:
29415294
44.

Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.

Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR.

J Crohns Colitis. 2018 May 25;12(6):653-661. doi: 10.1093/ecco-jcc/jjy003.

PMID:
29385469
45.

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT.

Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29.

46.

Neuromodulation via Interferential Electrical Stimulation as a Novel Therapy in Gastrointestinal Motility Disorders.

Moore JS, Gibson PR, Burgell RE.

J Neurogastroenterol Motil. 2018 Jan 30;24(1):19-29. doi: 10.5056/jnm17071. Review.

47.

Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response?

Rentsch C, Headon B, Ward MG, Gibson PR.

J Gastroenterol Hepatol. 2018 Jan;33(1):10-11. doi: 10.1111/jgh.14001. No abstract available.

PMID:
29284080
48.

The impact of exertional-heat stress on gastrointestinal integrity, gastrointestinal symptoms, systemic endotoxin and cytokine profile.

Snipe RMJ, Khoo A, Kitic CM, Gibson PR, Costa RJS.

Eur J Appl Physiol. 2018 Feb;118(2):389-400. doi: 10.1007/s00421-017-3781-z. Epub 2017 Dec 12.

PMID:
29234915
49.

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.

Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR.

J Crohns Colitis. 2018 Feb 28;12(3):289-297. doi: 10.1093/ecco-jcc/jjx146.

PMID:
29121178
50.

Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity.

Skodje GI, Sarna VK, Minelle IH, Rolfsen KL, Muir JG, Gibson PR, Veierød MB, Henriksen C, Lundin KEA.

Gastroenterology. 2018 Feb;154(3):529-539.e2. doi: 10.1053/j.gastro.2017.10.040. Epub 2017 Nov 2.

PMID:
29102613

Supplemental Content

Loading ...
Support Center